Duke Human Vaccine Institute

The Duke Human Vaccine Institute (DHVI) is the basic and translational arm of the Duke Global Health Institute in the area of emerging infections and related vaccine research and development.

DHVI has established a place of national and international leadership in the fight against the major infectious diseases. By focusing on the “bottlenecks” for the development of vaccines against HIV, TB, and other diseases, DHVI investigators are poised to make major new contributions to global health challenges. DHVI faculty are intimately involved in the work of the Center for HIV/AIDS Vaccine Immunology (CHAVI), a consortium of universities and academic medical centers established by the National Institute of Allergy and Infectious Diseases (NIAID), directed by Barton Haynes, MD, Director of the Duke Human Vaccine Institute. DHVI Investigators are also working on grants with the Collaboration for AIDS Vaccine Discovery (CAVD) funded by the Bill and Melinda Gates Foundation to facilitate HIV vaccine research. The CHAVI and the CAVD are two of the major scientific branches of the Global HIV/AIDS Vaccine Enterprise. Along with HIV vaccine research, DHVI is committed to developing drugs, vaccines, and diagnostics to protect against emerging infections such as avian influenza, plague, and SARS as well as bioterrorist threats. The Duke Global Health Research Building was built to house a national regional biocontainment facility to support this research.

The DHVI program in international research also promotes clinical research and training in diseases that threaten our global community. Current programs in Tanzania have successfully established collaborations between Duke and investigators in these countries to focus on such diseases as HIV/AIDS, tuberculoses and malaria.

More information about DHVI is available at http://dhvi.duke.edu/.